Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study

Neuropsychopharmacology. 2007 Oct;32(10):2057-66. doi: 10.1038/sj.npp.1301347. Epub 2007 Feb 28.

Abstract

Recent volumetric magnetic resonance imaging (MRI) studies have suggested brain volume changes in schizophrenia to be progressive in nature. Whether this is a global process or some brain areas are more affected than others is not known. In a 5-year longitudinal study, MRI whole brain scans were obtained from 96 patients with schizophrenia and 113 matched healthy comparison subjects. Changes over time in focal gray and white matter were measured with voxel-based morphometry throughout the brain. Over the 5-year interval, excessive decreases in gray matter density were found in patients in the left superior frontal area (Brodmann areas 9/10), left superior temporal gyrus (Brodmann area 42), right caudate nucleus, and right thalamus as compared to healthy individuals. Excessive gray matter density decrease in the superior frontal gray matter was related to increased number of hospitalizations, whereas a higher cumulative dose of clozapine and olanzapine during the scan interval was related to lesser decreases in this area. In conclusion, gray matter density loss occurs across the course of the illness in schizophrenia, predominantly in left frontal and temporal cortices. Moreover, the progression in left frontal density loss appears to be related to an increased number of psychotic episodes, with atypical antipsychotic medication attenuating these changes.

MeSH terms

  • Acute Disease / therapy
  • Adolescent
  • Adult
  • Antipsychotic Agents / pharmacology
  • Atrophy / etiology
  • Atrophy / pathology
  • Atrophy / prevention & control
  • Benzodiazepines / pharmacology
  • Brain / drug effects
  • Brain / pathology*
  • Brain / physiopathology
  • Caudate Nucleus / drug effects
  • Caudate Nucleus / pathology
  • Caudate Nucleus / physiopathology
  • Clozapine / pharmacology
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Frontal Lobe / drug effects
  • Frontal Lobe / pathology
  • Frontal Lobe / physiopathology
  • Humans
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Olanzapine
  • Schizophrenia / drug therapy
  • Schizophrenia / pathology*
  • Schizophrenia / physiopathology
  • Temporal Lobe / drug effects
  • Temporal Lobe / pathology
  • Temporal Lobe / physiopathology
  • Thalamus / drug effects
  • Thalamus / pathology
  • Thalamus / physiopathology
  • Time Factors

Substances

  • Antipsychotic Agents
  • Benzodiazepines
  • Clozapine
  • Olanzapine